Home > News > Recent cases

VPG Systems UK Limited v Air Weight Europe Limited [2015] EWHC 1862 (IPEC)1 July 2015On 1 July 2015 his Honour Judge Hacon handed down judgment in VPG Systems UK v Air-Weigh Europe [2015] EWHC 1862 in the Intellectual Property Enterprise Court. The action concerned alleged infringement of VPG’s patent for a type of on-board vehicle weighing system which uses an accelerometer or inclinometer to measure the change in angle […]
The Sofa Workshop Ltd v Sofaworks Ltd [2015] EWHC 1773 (IPEC) (29 June 2015)29 June 2015John Baldwin QC and Fiona Clark appeared for Sofaworks Limited, the Defendant, in this community trade mark infringement and passing off claim brought by The Sofa Workshop Limited  concerning two word CTMs for ‘SOFA WORKSHOP’. Sofaworks counterclaimed for revocation for non-use and invalidity. HHJ Hacon held that both CTMs were invalidly registered and liable for revocation […]
Actavis UK Ltd & Ors v Eli Lilly & Company [2015] EWCA Civ 555 (25 June 2015)25 June 2015Richard Meade QC and Isabel Jamal represented the Respondents/Claimants, Actavis, in this declaration of non-infringement (‘DNI’) appeal relating to a patent held by the Appellant/Defendant, Eli Lilly. The Patent concerned the use of pemetrexed disodium in the manufacture of a medicament for use in combination therapy. Actavis sought to use other pemetrexed salts (‘the active […]
Smith & Nephew Plc v Convatec Technologies Inc [2015] EWCA Civ 607 (24 June 2015)24 June 2015James Mellor QC and Charlotte May QC appeared for the Respondent/Appellant and Third Parties, ‘Smith & Nephew’, in this appeal which related to the construction of the words ‘between 1% and 25%’ as contained in the claim of a patent owned by the Appellant, ‘Convatec’. The patent concerns a process of silverisation of gel-forming fibres […]
Hospira UK Limited v Genentech Inc [2015] EWHC 1796 (Pat)24 June 2015Members of chambers recently appeared in this third of a series of actions brought by Hospira in relation to Genentech’s patents in respect of trastuzumab, marketed by Genentech under the trade mark Herceptin. This action concerned Genentech’s patent claiming the use of trastuzumab in combination with a taxane for the treatment of HER2-positive breast cancer, […]